CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Assembly Biosciences Doses First Two Participants in Phase 2 Trial of Hepatitis Delta Drug ABI-6250

By Public Technologies
  • Assembly Biosciences dosed the first two participants in a Phase 2 trial of oral ABI-6250 for chronic hepatitis delta virus infection.
  • The trial targets approximately 80 participants, testing two once-daily doses for safety and antiviral activity.
  • Initial Phase 2 data are expected in the fourth quarter of 2027.
  • Phase 1a results supported further development, with a mean half-life of approximately four days supporting once-daily dosing.
  • Gilead holds an exclusive licensing option for ABI-6250 for $90 million through Phase 2 completion and review of the option data package.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291600PRIMZONEFULLFEED9856448) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk